COMPASS Pathways (CMPS) Stock Overview
Operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CMPS Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
COMPASS Pathways plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.45 |
| 52 Week High | US$7.09 |
| 52 Week Low | US$2.25 |
| Beta | 1.94 |
| 1 Month Change | -17.42% |
| 3 Month Change | 24.15% |
| 1 Year Change | 0% |
| 3 Year Change | -50.72% |
| 5 Year Change | -84.75% |
| Change since IPO | -81.21% |
Recent News & Updates
Compass Pathways: Maintain Hold Rating With COMP360 Going Beyond TRD Development
Oct 15Is COMPASS Pathways (NASDAQ:CMPS) Using Debt Sensibly?
Aug 07
Recent updates
Compass Pathways: Maintain Hold Rating With COMP360 Going Beyond TRD Development
Oct 15Is COMPASS Pathways (NASDAQ:CMPS) Using Debt Sensibly?
Aug 07Compass Pathways: Betting On The Future Of Psilocybin Therapy
Feb 28Does COMPASS Pathways (NASDAQ:CMPS) Have A Healthy Balance Sheet?
Jan 04Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity
Nov 01Compass Pathways: Sector-Wide Reality Check Needed Post FDA Lykos MDMA Decision
Aug 19Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies
Jul 08Psychedelics Closer To Commercialization; Compass Far And Away The Leader
May 23COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?
Apr 25Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play
Feb 08Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth
Dec 06Booker again pushes for easier access to psychedelics for terminally ill patients
Oct 19Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation
Aug 13COMPASS Pathways And The Trillion Dollar Opportunity
Aug 11COMPASS Pathways ADS Q2 2022 Earnings Preview
Aug 03COMPASS Pathways names new CEO
Jul 19Compass Pathways: Shares Look Cheap But Proving Psilocybin Case Won't Be Easy
Jun 30We're Hopeful That COMPASS Pathways (NASDAQ:CMPS) Will Use Its Cash Wisely
Apr 28Checking In On Compass Pathways
Mar 02We Think COMPASS Pathways (NASDAQ:CMPS) Can Afford To Drive Business Growth
Dec 29Compass Pathways: Psychedelics For Mental Health
Nov 23Compass Faces Tricky Road To Approval For Its Psychedelic Depressive Therapy
Sep 17Shareholder Returns
| CMPS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.8% | -0.6% | -2.0% |
| 1Y | 0% | -1.1% | 12.1% |
Return vs Industry: CMPS matched the US Biotechs industry which returned 0.3% over the past year.
Return vs Market: CMPS underperformed the US Market which returned 12.3% over the past year.
Price Volatility
| CMPS volatility | |
|---|---|
| CMPS Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CMPS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CMPS's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 166 | Kabir Nath | compasspathways.com |
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.
COMPASS Pathways plc Fundamentals Summary
| CMPS fundamental statistics | |
|---|---|
| Market cap | US$536.31m |
| Earnings (TTM) | -US$237.32m |
| Revenue (TTM) | n/a |
Is CMPS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMPS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$237.32m |
| Earnings | -US$237.32m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 83.2% |
How did CMPS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/07 13:55 |
| End of Day Share Price | 2025/11/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
COMPASS Pathways plc is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Charles Duncan | Cantor Fitzgerald & Co. |